MARKET

CALC

CALC

CALCIMEDICA INC
NASDAQ
1.220
-0.020
-1.61%
Pre Market: 1.358 +0.138 +11.30% 08:23 11/13 EST
OPEN
1.289
PREV CLOSE
1.240
HIGH
1.402
LOW
1.180
VOLUME
164
TURNOVER
0
52 WEEK HIGH
36.00
52 WEEK LOW
1.000
MARKET CAP
8.41M
P/E (TTM)
-0.2803
1D
5D
1M
3M
1Y
5Y
1D
What Makes CalciMedica Inc. (CALC) a New Buy Stock
NASDAQ · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Acrivon Therapeutics, Inc. (ACRV), Black Diamond Therapeutics (BDTX) and CalciMedica (CALC)
TipRanks · 2d ago
CalciMedica GAAP EPS of -$0.24 beats by $1.03
Seeking Alpha · 3d ago
CalciMedica Q3 EPS $(0.24) Beats $(1.27) Estimate
Benzinga · 3d ago
Press Release: CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
Dow Jones · 3d ago
Weekly Report: what happened at CALC last week (1102-1106)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 11/02 12:05
Weekly Report: what happened at CALC last week (1026-1030)?
Weekly Report · 11/02 09:46
More
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).

Webull offers Calcimedica Inc stock information, including NASDAQ: CALC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CALC stock methods without spending real money on the virtual paper trading platform.